ObjectiveTo analyze the recent clinical results of emergency conversion of transcatheter aortic valve replacement (TAVR) to surgery, and summarize the clinical experience. Methods The clinical data of patients who underwent TAVR emergency conversion surgery in the Department of Cardiovascular Surgery of the Second Hospital of Hebei Medical University from 2018 to 2023 were collected, and the results of 1-month follow-up after surgery were recorded. Results Totally 253 patients underwent TAVR, and 11 patients underwent emergency conversion to surgery, with an emergency conversion rate of 4.3%. Among the 11 patients, 7 were males and 4 were females, with an average age of 69.55±5.01 years. The causes of urgent conversion to surgery in TAVR were valve stent displacement (63.6%), left ventricular perforation and rupture (18.2%), and a large amount of perivalvular reflux (18.2%) after the insertion of the second valve. One patient died intraoperative, with a perioperative mortality rate of 9.1%. Among the 10 surviving patients, 8 had pulmonary infection, 7 severe pneumonia, 3 pleural effusion, 8 liver function injury, 3 renal function injury, 5 upper gastrointestinal bleeding, 1 cerebrovascular complications, 1 atrial fibrillation, 1 ventricular premature contraction, 1 atrioventricular block, and 3 complete left bundle branch block. After one month of postoperative follow-up, one patient died. The 30-day mortality rate after TAVR emergency conversion surgery was 18.2%, and the quality of life of 9 patients (81.8%) improved significantly compared to before surgery. There were no readmission patients with cardiovascular system diseases. Conclusion The incidence of emergency conversion to surgery in TAVR is low, but the incidence of surgical complications is high, and the 30-day postoperative mortality rate is also high. When severe complications occur during TAVR surgery, emergency conversion to surgical surgery can still bring good early clinical results for most patients.
ObjectiveTo investigate the new-onset conduction block after transcatheter aortic valve replacement (TAVR) and summarize the relevant experience. Methods The perioperative data of TAVR patients in the Second Hospital of Hebei Medical University from 2016 to 2023 were collected, and the new-onset incidence of conduction block after TAVR was analyzed retrospectively. ResultsThere were 352 patients of TAVR operation (256 patients of Venus-A, 69 patients of Vita-Flow, 27 patients of J-Valve), among whom 38 (10.8%) patients of new-onset postoperative block. There were 6 (1.7%) patients of new-onset postoperative grade Ⅲ atrioventricular block, including 5 (2%) patients of Venus A and 1 (1.4%) patient of Vita-Flow. Conduction function was restored in 2 patients within 14 days after surgery, and failed to be restored in 4 patients, who then received permanent pacemaker implantation in the department of cardiology. There were 27 (7.7%) patients of new left bundle branch block after surgery, including 22 (8.6%) patients of Venus-A , 4 (5.8%) patients of Vita-Flow and 1 (3.7%) patient of J-Valve; and conduction function was restored within 7 days after surgery in 23 patients, and 5 (1.4%) patients developed new right bundle branch blocks after surgery including 4 (1.5%) patients of Venus-A and 1 (1.4%) patient of Vita-Flow. Conclusion New-onset block is a common complication after TAVR, the new-onset rate of left bundle branch block is the highest, followed by the grade Ⅲ atrioventricular block. Mastering reasonable methods and applying appropriate strategies can also effectively reduce the new rate of postoperative conduction block and improve the overall success rate of TAVR surgery.
Objective To evaluate the short-term efficacy of transcatheter aortic valve replacement (TAVR) using Venus A-Plus valve delivery system in patients with severe aortic stenosis. Methods The clinical data of patients undergoing TAVR in our hospital from August 2018 to March 2022 were collected and divided into a Venus A-PLUS and a Venus A group according to the type of valve delivery system used. The perioperative data of the two groups were compared. ResultsA total of 121 patients were included, including 70 patients in the Venus A-Plus group (45 males and 25 females with a mean age of 67.81±6.62 years), and 51 patients in the Venus A group (33 males and 18 females with a mean age of 68.25±7.01 years). All patients underwent TAVR, and the postoperative hemodynamic features (left ventricular ejection fraction, mean cross-valve pressure difference, peak flow rate) were significantly improved (P<0.05). There was no statistical difference in surgical success rate, all-cause mortality, conversion to thorax opening, midvalve placement, moderate or above perivalvular regurgitation, new left bundle branch block or new right bundle branch block between the two groups (P>0.05). Conclusion TAVR with Venus A-Plus valve delivery system in patients with severe aortic stenosis is satisfactory, safe and reliable.
ObjectiveTo analyze the short-term clinical efficacy and prognosis of one-stop transcatheter aortic valve replacement (TAVR)+percutaneous coronary intervention (PCI) in the treatment of aortic valve disease with coronary heart disease. MethodsThe clinical data of patients with aortic valve disease complicated with coronary heart disease who underwent one-stop TAVR+PCI treatment at the Department of Cardiovascular Surgery, the Second Hospital of Hebei Medical University from January 2018 to June 2023 were retrospective analyzed. The preoperative and postoperative clinical data were compared, and 1-month follow-up results were recorded. ResultsA total of 37 patients were enrolled, including 22 males and 15 females, with an average age of 69.14±6.47 years. Thirty-six patients recovered and were discharged after the surgery, and 1 (2.7%) patient died during the surgery. Self-expanding TAVR valves were implanted through the femoral artery in all patients. One coronary artery was opened by PCI in 35 (94.6%) patients, and two coronary arteries were opened by PCI in 2 (5.4%) patients. All PCI opened arteries had a stenosis>70%. During the postoperative hospitalization, the complications included pulmonary infection in 11 (30.6%) patients, severe pneumonia in 10 (27.8%) patients, liver function injury in 14 (38.9%) patients, renal function injury in 5 (13.9%) patients, cerebral infarction in 1 (2.8%) patient, atrial fibrillation in 1 (2.8%) patient, ventricular premature beats in 2 (5.6%) patients, atrioventricular block in 2 (5.6%) patients, and complete left bundle branch block in 5 (13.9%) patients. The median postoperative ventilation assistance time was 12.0 (0.0, 17.0) h, the ICU monitoring time was 1.0 (0.0, 2.0) d, and the postoperative hospitalization time was 5.0 (4.0, 7.0) d. There was a significant improvement in the New York Heart Association cardiac function grading after surgery (P<0.001). After surgery, there were 21 (58.3%) patients had minor perivalve leakage, 6 (16.7%) patients had minor to moderate perivalve leakage, and no moderate or above degree of perivalve leakage. After one month of postoperative follow-up, 36 patients showed significant improvement in heart function. There were no patients with recurrent acute coronary syndrome, re-PCI, or cardiovascular system disease related re-hospitalization. ConclusionThe one-stop TAVR+PCI treatment for patients with aortic valve disease and coronary heart disease can obtain satisfactory short-term clinical efficacy, which is worth further trying and studying.